TEI 6472
Latest Information Update: 19 Oct 2000
Price :
$50 *
At a glance
- Originator Teijin Pharma
- Class Antiallergics; Antiasthmatics; Benzoic acids
- Mechanism of Action Histamine release inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for Allergic asthma in Japan (Unknown route)
- 31 Aug 1998 No-Development-Reported for Allergic asthma in Japan (Unknown route)
- 29 Aug 1996 New profile